NSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin.

NSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin.

The GM2 gangliosidoses are caused by incomplete catabolism of GM2 ganglioside in the lysosome, leading to progressive storage and a neurodegenerative clinical course. An inflammatory response (microglial activation, macrophage infiltration, oxidative damage) has been found to be a consequence of GM2...

Full description

Bibliographic Details
Main Authors:	Jeyakumar, M, Smith, D, Williams, I, Borja, M, Neville, D, Butters, T, Dwek, R, Platt, F
Format:	Journal article
Language:	English
Published:	2004

Similar Items

Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease.
by: Andersson, U, et al.
Published: (2004)

Inhibition of calcium uptake via the sarco/endoplasmic reticulum Ca2+-ATPase in a mouse model of Sandhoff disease and prevention by treatment with N-butyldeoxynojirimycin.
by: Pelled, D, et al.
Published: (2003)

Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease
by: Ulrika Andersson, et al.
Published: (2004-08-01)

Enhanced survival in Sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantation.
by: Jeyakumar, M, et al.
Published: (2001)

Restricted ketogenic diet enhances the therapeutic action of N-butyldeoxynojirimycin towards brain GM2 accumulation in adult Sandhoff disease mice.
by: Denny, C, et al.
Published: (2010)

N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo.
by: Andersson, U, et al.
Published: (2000)

Long-term non-hormonal male contraception in mice using N-butyldeoxynojirimycin.
by: Walden, C, et al.
Published: (2006)

N-butyldeoxynojirimycin causes weight loss as a result of appetite suppression in lean and obese mice.
by: Priestman, D, et al.
Published: (2008)

Severe endothelial dysfunction in the aorta of a mouse model of Fabry disease; partial prevention by N-butyldeoxynojirimycin treatment.
by: Heare, T, et al.
Published: (2007)

Analysis of stored oligosaccharides in a mouse model of a glycolipid storage (Sandhoff) disease
by: Awan, F, et al.
Published: (2003)

MRS reveals additional hexose N-acetyl resonances in the brain of a mouse model for Sandhoff disease.
by: Lowe, J, et al.
Published: (2005)

The alpha-glucosidase inhibitor N-butyldeoxynojirimycin inhibits human immunodeficiency virus entry at the level of post-CD4 binding.
by: Fischer, P, et al.
Published: (1995)

Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis.
by: Cox, T, et al.
Published: (2000)

N -butyldeoxynojirimycin reduces growth and ganglioside content of experimental mouse brain tumours.
by: Ranes, M, et al.
Published: (2001)

Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease.
by: Elstein, D, et al.
Published: (2004)

Beneficial effects of acetyl-DL-Leucine (ADLL) in a mouse model of Sandhoff disease
by: Kaya, E, et al.
Published: (2020)

Beneficial Effects of Acetyl-DL-Leucine (ADLL) in a Mouse Model of Sandhoff Disease
by: Ecem Kaya, et al.
Published: (2020-04-01)

Iminosugar-based inhibitors of glucosylceramide synthase increase brain glycosphingolipids and survival in a mouse model of Sandhoff disease.
by: Karen M Ashe, et al.
Published: (2011-01-01)

Substrate reduction therapy in mouse models of the glycosphingolipidoses.
by: Platt, F, et al.
Published: (2003)

N-Butyldeoxynojirimycin is a broadly effective anti-HIV therapy significantly enhanced by targeted liposome delivery.
by: Pollock, S, et al.
Published: (2008)

Gene Expression Profile in the Sandhoff Mouse Brain with Progression of Age
by: Kshitiz Singh, et al.
Published: (2022-11-01)

An inducible mouse model of late onset Tay-Sachs disease.
by: Jeyakumar, M, et al.
Published: (2002)

Glycosphingolipid profiling of tissues from mouse models of human lysosomal storage disorders
by: Priestman, D, et al.
Published: (2008)

Infantile Sandhoff's disease
by: K Sass, et al.
Published: (2009-08-01)

Circadian profiling in two mouse models of lysosomal storage disorders; Niemann Pick type-C and Sandhoff disease.
by: Richardson, K, et al.
Published: (2016)

Storage solutions: treating lysosomal disorders of the brain.
by: Jeyakumar, M, et al.
Published: (2005)

Glycosphingolipid lysosomal storage diseases: therapy and pathogenesis.
by: Jeyakumar, M, et al.
Published: (2002)

Glycosphingolipid storage leads to the enhanced degradation of the B cell receptor in Sandhoff disease mice.
by: te Vruchte, D, et al.
Published: (2010)

Design, synthesis, and biological evaluation of enantiomeric beta-N-acetylhexosaminidase inhibitors LABNAc and DABNAc as potential agents against Tay-Sachs and Sandhoff disease.
by: Rountree, J, et al.
Published: (2009)

Efficacy of a Bicistronic Vector for Correction of Sandhoff Disease in a Mouse Model
by: Evan Woodley, et al.
Published: (2019-03-01)

New developments in treating glycosphingolipid storage diseases.
by: Platt, F, et al.
Published: (2005)

Effects of N-butyldeoxynojirimycin and the Lec3.2.8.1 mutant phenotype on N-glycan processing in Chinese hamster ovary cells: application to glycoprotein crystallization.
by: Butters, T, et al.
Published: (1999)

N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal sandhoff diseased mice
by: Baek, R, et al.
Published: (2004)

Substrate reduction therapy reduces brain ganglioside GM2 in neonatal Sandhoff disease mice
by: Baek, R, et al.
Published: (2005)

N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice.
by: Baek, R, et al.
Published: (2008)

Beneficial effects of substrate reduction therapy in a mouse model of GM1 gangliosidosis.
by: Elliot-Smith, E, et al.
Published: (2008)

Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis.
by: Jeyakumar, M, et al.
Published: (2003)

Decrease in Myelin-Associated Lipids Precedes Neuronal Loss and Glial Activation in the CNS of the Sandhoff Mouse as Determined by Metabolomics
by: Emmanuelle Lecommandeur, et al.
Published: (2020-12-01)

N-butyldeoxynojirimycin delays motor deficits, cerebellar microgliosis, and Purkinje cell loss in a mouse model of mucolipidosis type IV
by: Lauren C. Boudewyn, et al.
Published: (2017-09-01)

Antiviral effect of N-butyldeoxynojirimycin against bovine viral diarrhea virus correlates with misfolding of E2 envelope proteins and impairment of their association into E1-E2 heterodimers.
by: Branza-Nichita, N, et al.
Published: (2001)